You are here

Europe's 'FDA' in limbo as hidden costs of Brexit continue to mount

London-based European Medicines Agency's bid to relocate sends tremors through UK's drug industry, raises public-safety concerns

“The consequence, and the direct impact on the public health, is my main concern. Imagine if we are late in reaction for some crisis, something going wrong. . . If we are not in a position to intervene fast and efficiently, that is a serious threat to public health.” - Guido Rasi, executive director of the European Medicines Agency


WHEN it switched offices in London not long ago, the European Medicines Agency (EMA) signed a 25-year lease on a shiny new building in the east of the city.

Just two years later, the organisation is preparing to relocate again, but this time its likely move has sent tremors...

Market voices on: